USFDA warns Cipla for lapses in manufacturing practices at Pithampur facility
According to an exchange filing, the drug manufacturer was given a detailed breakdown of the lapses in methods followed at the facility by the USFDA. "This warning letter summarizes contraventions regarding methods or controls followed at the facility which do not conform to the prescribed cGMP regulations and contains directional guidance for necessary corrections," the filing said.
Disclaimer : Mytimesnow (MTN) lets you explore worldwide viral news just by analyzing social media trends. Tap read more at source for full news. The inclusion of any links does not necessarily imply any endorsement of the views expressed within them.
